NT5C2 and colorectal carcinoma: When treating non-small cell lung cancer cells with gemcitabine and platinum, the expression of NT5C2 can be used as an indicator of response.[13,14] In hepatocellular carcinoma, NT5DC2 increases tumor cell proliferation by upregulating EGFR expression[15] and can be used as a prognostic biomarker.[16] Zhu et al[17] revealed that colorectal carcinoma cells were reduced when NT5DC2 expression was suppressed, resulting in a reduction in proliferation, migration, invasion and infiltration of tumor-associated macrophages.